Related Experiment Video
Updated: Oct 10, 2025
05:58
Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells
Published on: October 13, 2023
1.4K
A Graphene Oxide-interfaced Microfluidics System for Isolating and Capturing Circulating Tumor Cells and Microemboli
Summary
This study introduces a microfluidics system for highly sensitive detection and capture of circulating tumor cells (CTCs) and circulating tumor microemboli (CTMs). This technology aids in early cancer diagnosis and preventing recurrence by isolating rare cancer cells from blood.
Area of Science:
- Biomedical Engineering
- Oncology
- Microfluidics
Background:
- Circulating tumor cells (CTCs) and circulating tumor microemboli (CTMs) are rare cells in peripheral blood, crucial indicators of cancer metastasis.
- The diverse phenotypes of CTCs and CTMs necessitate methods for detecting both single and aggregated forms to assess cancer aggressiveness.
- Early diagnosis and prevention of cancer recurrence rely on the sensitive detection and capture of these rare cell populations.
Purpose of the Study:
- To develop and present a novel microfluidics system for the isolation and highly sensitive capture of CTCs and CTMs.
- To enable multiplex detection of CTCs and CTMs with high specificity and biocompatibility.
- To provide a tool for improved early-stage cancer diagnosis and monitoring of metastasis.
Main Methods:
- Utilized a microfluidics system incorporating a serpentine channel and bifurcating micro-channels for separating CTCs and CTMs from other blood components.
- Developed a graphene oxide interface on a glass slide for antibody conjugation.
- Employed click chemistry for efficient and specific antibody attachment to the graphene oxide surface for capturing CTCs and CTMs.
Main Results:
- Successfully demonstrated the separation of CTCs and CTMs from blood using the designed microfluidic channels.
- Achieved highly sensitive and specific capture of CTCs and CTMs via antibody-functionalized graphene oxide.
- The system exhibited good biocompatibility, preserving the integrity of captured cells.
Conclusions:
- The developed microfluidics system effectively isolates and captures CTCs and CTMs, offering a promising approach for cancer diagnostics.
- The combination of microfluidics and graphene oxide-based antibody conjugation enables sensitive, specific, and multiplexed detection of circulating tumor cells.
- This technology holds potential for advancing early cancer detection, monitoring metastatic disease, and guiding treatment strategies.
